Emily Parker @911GlobalMeds
08 March, 02:35
Evolving role of zoledronic acid in early breast cancer

Most women diagnosed in the early stages of breast cancer are likely to have a great prognosis. It is also likely that they remain disease free for several years after their treatment ends.

However, the side effects of such treatments associated with bone issues are also likely to have effect the patient's bone health in the long run.

The bone loss associated with breast cancer therapy like endocrine therapy may contribute towards the risk of osteoporosis and bone fractures in the long run.

Several guidelines for treatment are now changed to include the need for preserving bone health in adjuvant therapy regimes and any measures involved.

Source: https://shorturl.at/gnZ68


Notice: Undefined index: tg1tga_access in /home/admin/www/anonup.com/themes/default/apps/timeline/post.phtml on line 396

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.